MORRISVILLE, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Syneos Health, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Simon Bartle as Chief Human Resources Officer, effective immediately. Bartle will lead the Company’s people strategy, scaling the capabilities and culture that drive breakthrough clinical and commercial performance. Bartle joins Syneos Health with 25 years of extensive human resources (HR) experience in complex, global organizations. He m ...

Core Insights - Certara, Inc. reported a total revenue of $104.6 million for Q3 2025, reflecting a year-over-year growth of 10% [4][8] - The company has raised its profitability targets for 2025 and narrowed its revenue guidance to a range of $415 million to $420 million [3][15] - The CEO emphasized the launch of new software products, particularly CertaraIQ for QSP modeling, aimed at enhancing biosimulation technology in drug development [3] Financial Performance - Total revenue for Q3 2025 was $104.6 million, with software revenue at $43.8 million (22% growth) and services revenue at $60.8 million (3% growth) [4][5][8] - Total bookings reached $96.6 million, a 1% increase year-over-year, with software bookings growing by 17% [6][8] - Net income for Q3 2025 was $1.5 million, a significant improvement from a net loss of $1.4 million in Q3 2024, marking a 211% increase [12][8] Cost and Expenses - Total operating expenses for Q3 2025 were $61.9 million, up from $55.0 million in Q3 2024, primarily due to increased employee-related costs and stock-based compensation [10][8] - The cost of revenues was $39.7 million, an increase from $37.2 million in the same quarter last year [7][8] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $35.2 million, a 7% increase from $33.1 million in Q3 2024 [11][8] - Adjusted net income for Q3 2025 was $22.2 million, compared to $20.3 million in Q3 2024 [13][8] - Adjusted diluted earnings per share for Q3 2025 was $0.14, slightly up from $0.13 in Q3 2024 [13][8] Guidance and Outlook - The company expects full-year adjusted EBITDA margin to be approximately 32% and adjusted diluted earnings per share in the range of $0.45 to $0.47 [15] - Certara aims to continue investing in R&D and commercial efforts to ensure sustainable long-term growth [3]

Core Viewpoint - Certara, Inc. will release its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call to discuss the results [1]. Company Overview - Certara is a global leader in biosimulation, utilizing software, technology, and services to enhance drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Event Details - A conference call will be held at 5:00 PM ET on the same day as the financial results release, and investors must register online to participate [1]. - It is recommended that investors register at least one day in advance [1]. - A live and archived webcast of the event will be available on Certara's website [2].

Financial Data and Key Metrics Changes - The company reported revenue of $1,030 million in Q2 2025, a 0.6% increase year over year, with nearly half of the revenue outperformance driven by foreign exchange [9][10] - Organic revenue declined by 0.5%, primarily due to a low single-digit decline in the DSA segment, partially offset by low single-digit increases in RMS and manufacturing segments [10][12] - The operating margin improved to 22.1%, an increase of 80 basis points year over year, reflecting cost savings from restructuring and better sales volume [10][11] Business Line Data and Key Metrics Changes - DSA segment revenue was $618 million, a 2.4% decrease year over year on an organic basis, driven by lower revenue for discovery services [13] - RMS revenue increased by 2.3% on an organic basis to $213.3 million, primarily driven by the timing of NHP shipments and higher revenue for research model services [21][22] - Manufacturing segment revenue was $200.8 million, a 2.9% increase on an organic basis, driven by growth in microbial solutions [25][26] Market Data and Key Metrics Changes - Revenue for small and mid-sized biotech clients improved slightly for the third consecutive quarter, while revenue for global biopharmaceutical clients remained below last year's level but improved sequentially [10][21] - The demand environment for global biopharmaceutical clients appears to be stabilizing, with proposal activity increasing both year over year and sequentially [15][50] - The academic and government client segments saw revenue increases despite potential NIH budget cuts, with only a minor impact observed [22] Company Strategy and Development Direction - The company is focused on expanding its NAMS portfolio and enhancing scientific capabilities to support biopharmaceutical companies in transitioning to alternative technologies [19][20] - A strategic review is underway to evaluate avenues for value creation, including portfolio and capital allocation strategies [28][29] - The company aims to generate over $175 million in cost savings this year, contributing to improved financial performance [11][44] Management's Comments on Operating Environment and Future Outlook - Management noted that the global biopharmaceutical demand trends appear to have bottomed and are beginning to slowly move upward [7] - The company raised its revenue and non-GAAP earnings per share guidance due to outperformance in Q2, reflecting a more favorable demand environment [12][33] - There is recognition of ongoing uncertainty in the healthcare landscape, but management remains optimistic about stabilization in demand [8][9] Other Important Information - The company experienced a slight decline in DSA backlog to $1.93 billion, with gross and net bookings improving at mid-single-digit rates year over year [14] - The non-GAAP tax rate increased to 22.7%, primarily due to stock-based compensation, but was more favorable than expected [40][41] - Free cash flow for Q2 was strong at $169.3 million, driven by higher earnings and improved working capital [42][43] Q&A Session Summary Question: Current demand environment and pharma's perspective - Management indicated that the demand situation is stabilizing for pharma, with some demand trends having bottomed [48] - Revenue and proposals are up, but cancellations have also increased, particularly for longer-term post-IND work [49][50] Question: Clarification on revenue guidance and book-to-bill ratio - Management stated that the current book-to-bill ratio is expected to remain in the range of 0.8 to 0.93, which does not require improvement to meet guidance [55] Question: CDMO performance and revenue impact - The CDMO revenue headwind is expected to be around $20 million due to the wind-down of a client relationship, with higher margins noted in the first half [62][63] Question: Backlog conversion and revenue support - Management believes the backlog is stable and robust, allowing for continued drawing from it to replace studies that slip or cancel [72][74] Question: Hiring confidence and future growth - Management expressed confidence in hiring to meet current demand, with improvements in the overall demand curve expected to support future growth [78][79] Question: Pricing stability and margin implications - Pricing in DSA remains stable, with mix favorability contributing positively to margins [82][84] Question: Cancellations in longer-term work - Cancellations are not expected to significantly impact margins, as the margin profile for different types of work is often comparable [86]

Core Viewpoint - Certara, Inc. will release its financial results for Q2 2025 on August 6, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Investor Information - Investors interested in the conference call must register online, with a recommendation to do so at least one day in advance [1]. - A live and archived webcast of the conference call will be available on the "Investors" section of Certara's website [2]. Contact Information - Investor Relations contact is David Deuchler from Gilmartin Group [4]. - Media contact is Alyssa Horowitz [4].

Group 1 - Simulations Plus (SLP) share price dropped significantly after the company reported preliminary Q3 FY25 results that did not meet expectations [1] - The current weakness in Simulations Plus is attributed to soft biopharma market conditions and the company's relatively large services business [1] Group 2 - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations due to misunderstandings of long-term business prospects [1] - Narweena aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights [1] Group 3 - Narweena has a high risk appetite and a long-term investment horizon, seeking deeply undervalued stocks, particularly in smaller cap markets [1] - The firm believes that an aging population with low growth and stagnating productivity will create new investment opportunities [1] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 4 - The economic landscape is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia over time [1]

Core Insights - Charles River Laboratories International, Inc. (CRL) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.34, a 3.1% increase year over year, exceeding the Zacks Consensus Estimate by 13.6% [1] - Total revenues for the first quarter reached $984.2 million, surpassing the Zacks Consensus Estimate by 5.2%, but reflecting a 2.4% decline from the previous year [2] - The company raised its 2025 guidance, indicating improved net bookings in the Discovery and Safety Assessment (DSA) segment [12] Financial Performance - The gross profit for the quarter was $317.7 million, down 7.9% from the prior year, with a gross margin of 32.3%, contracting 181 basis points year over year [7] - Selling, general & administrative expenses decreased by 4.6% year over year to $177.8 million, while adjusted operating profit fell 11.7% to $139.9 million [7] - The company exited the first quarter with cash and cash equivalents of $229.4 million, an increase from $194.6 million at the end of the previous quarter [8] Segment Performance - Research Models and Services (RMS) revenues totaled $213.1 million, down 3.5% year over year, primarily due to timing of shipments in China and lower revenues in the Cell Solutions business [4] - Discovery and Safety Assessment (DSA) revenues amounted to $592.6 million, a decline of 2.1% year over year, attributed to lower revenues for discovery services [5] - Manufacturing Solutions revenues were $178.5 million, down 3.6% year over year, mainly due to declines in CDMO and Biologics Testing businesses [6] Shareholder Returns - During the first quarter, the company repurchased 2.1 million shares for a total of $350 million, with a remaining authorization of $549.3 million under its $1 billion stock repurchase program [9] 2025 Guidance - For 2025, CRL expects total revenues to decline in the range of 5.5%-3.5%, an improvement from the earlier estimate of 4.5%-7% [10] - Adjusted EPS for 2025 is projected to be in the range of $9.30-$9.80, up from the previous range of $9.10-$9.60 [11]

Core Viewpoint - Certara, Inc. has announced its preliminary financial results for Q1 2025, highlighting strong revenue growth and a stock repurchase program of up to $100 million, reflecting confidence in its long-term strategy and AI investments [2][3][6]. Financial Performance - Expected revenue for Q1 2025 is projected at $106.0 million, a 10% increase from $96.7 million in Q1 2024 [6]. - Software revenue is anticipated to be $46.4 million, up 18% from $39.3 million in Q1 2024 [6]. - Services revenue is expected to reach $59.6 million, a 4% increase from $57.3 million in Q1 2024 [6]. - Total bookings for Q1 2025 are projected at $118.0 million, representing a 12% growth compared to $105.8 million in Q1 2024 [6]. - Adjusted EBITDA is expected to be in the range of $33-$35 million, reflecting a growth of 13-20% from $29.1 million in Q1 2024 [6]. Full-Year Guidance - Certara reiterates its full-year 2025 revenue guidance of $415 million to $425 million [7]. - The adjusted EBITDA margin for the full year is expected to be between 30-32% [7]. - Adjusted diluted earnings per share is projected to be in the range of $0.42 - $0.46 [7]. - Fully diluted shares are expected to be between 162 million to 164 million [7]. Strategic Initiatives - The company is conducting a strategic review of its regulatory services business and is in preliminary discussions with external parties [8]. - Arsenal Capital Partners has agreed to a one-year lock-up on shares acquired in a December 2022 transaction, indicating ongoing support for Certara's growth [3][6]. Upcoming Events - Certara will host a conference call on May 5, 2025, to discuss its Q1 2025 financial results, with registration required for investors [9].

Core Viewpoint - Certara, Inc. has reported strong preliminary financial results for Q1 2025, with significant growth in revenue and bookings, and has reiterated its full-year guidance for 2025 [2][6]. Financial Performance - Expected revenue for Q1 2025 is $106.0 million, a 10% increase from $96.7 million in Q1 2024 [7]. - Software revenue is projected at $46.4 million, up 18% from $39.3 million in the same quarter last year [7]. - Services revenue is expected to be $59.6 million, reflecting a 4% growth from $57.3 million in Q1 2024 [7]. - Total bookings for Q1 2025 are anticipated to be $118.0 million, a 12% increase from $105.8 million in Q1 2024 [7]. - Adjusted EBITDA is estimated to be in the range of $33-$35 million, representing a growth of 13-20% compared to $29.1 million in Q1 2024 [7]. Full-Year Guidance - The company maintains its full-year 2025 revenue guidance in the range of $415 million to $425 million [8]. - Adjusted EBITDA margin for the full year is expected to be between 30-32% [8]. - Adjusted diluted earnings per share is projected to be in the range of $0.42 - $0.46 [8]. Strategic Developments - Arsenal Capital Partners has agreed to a one-year lock-up on shares acquired from EQT, indicating continued support for Certara's growth [3][6]. - Certara is actively pursuing a strategic evaluation of its regulatory services business, engaging in preliminary discussions with external parties [9]. Share Repurchase Program - The Board of Directors has authorized a stock repurchase program allowing for the repurchase of up to $100 million of outstanding common stock, reflecting confidence in the company's strategy [2][3].